Search

Renown Health and the University of Nevada, Reno School of Medicine give the gift of early diagnosis and disease prevention this holiday season.   With the season of giving upon us, give yourself the gift of health. The Renown Institute for Health Innovation (IHI) and the University of Nevada, Reno School of Medicine (UNR Med) are excited to offer a free Enhanced Liver Fibrosis (ELFTM) test to patients at risk for a common type of liver disease, e.g. metabolic and nonalcoholic steatohepatitis (M/NASH), and who enroll or are currently enrolled in the Healthy Nevada Project. The ELF Test is an FDA (Food and Drug Administration) approved non-invasive test to help identify people most at risk for liver scarring, e.g. cirrhosis, and allows doctors to intervene before irreversible damage occurs. If undetected and untreated, M/NASH can result in liver cirrhosis which could require liver transplantation or lead to death. This test is important as the symptoms of M/NASH can be silent or non-specific, making it difficult to diagnose.  “There are currently more than 11,000 people across the U.S. on the national liver transplant waiting list, and with the heightened prevalence of NAFLD and M/NASH, this number is projected to keep rising; however, with research such as the ELF Test at our disposal, we are continuing to find ways to improve the health of those at risk for advanced liver disease,” said Bill Plauth, MD, Chief Medical Officer for Renown Health and Associate Dean of Clinical Affairs at UNR Med. “We encourage our community to participate in this early risk detection. Through this sophisticated, noninvasive, blood test, our physicians and Advanced Practice Providers can better evaluate liver fibrosis to help those affected and enable researchers to improve the prevention and treatment of nonalcoholic liver disease as a whole.”  This liver health-focused sub-study of the Healthy Nevada Project seeks to enhance the understanding of both NAFLD and M/NASH and to help inform the development of treatment options for these conditions, as few currently exist. “Providing access to cutting-edge innovations such as the ELF Test is critical for both participants and the physicians and advanced practice providers that care for them.” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project and the Liver Disease Study and research professor at UNR Med. Those interested in determining their risk for M/NASH and its progression are encouraged to enroll in the Metabolic & Nonalcoholic Steatohepatitis study. Those who have consented and participated in the M/NASH research will be eligible and contacted with more information on how to receive the ELF Test. The Renown IHI is also happy to connect with physicians and Advanced Practice Providers interested in having their patients enroll in the Healthy Nevada Project and join the study. For members of the community who would like more information and learn how to enroll, please contact the Renown IHI at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About the ELF™ Test  The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. For more information or to enroll, please contact RenownIHI@renown.org or (775) 982-6914. In the U.S., the ELF Testing Service is available from Brio Clinical, Inc., a CLIA-certified laboratory offering specialized testing throughout the United States. Brio Clinical is regulated under CLIA as qualified to perform high complexity testing.

Read More About Give the Gift of Health This Season with ELF Testing

Three-day medical education conference advances research, education, prevention and treatment. Physicians and medical professionals from throughout the Mountain West will soon be convening in Lake Tahoe to explore emerging treatments, the most recent advances and new clinical guidelines for the diagnosis, treatment and prevention of cardiovascular disease, diabetes mellitus, stroke and heart disease. Hosted by Renown's Institute for Heart & Vascular Health and the Nevada Academy of Family Physicians, the three-day Trends in Cardiovascular Medicine conference will bring together national experts to explore challenges and solutions to cardiovascular diseases, the leading cause of death globally, taking an estimated 17.9 million lives each year. "Our mission is to advance health in America. As Nevada's first integrated health system, with our University of Nevada, Reno School of Medicine affiliation, we are advancing health and health care through world-class medical education, clinical research and patient care for our community, our state and our nation," says Anthony D. Slonim, MD, DrPH, President & CEO, Renown Health. "And, we have so much work to do. In 2019, 9.5% of Nevadans reported being told by a health professional that they had angina or coronary heart disease; which is significantly above the national average of 8.4%. As public health and health care providers, we can do more to encourage people to adopt healthy lifestyle habits to keep their heart healthy and help prevent heart disease through the Healthy Nevada Project®, where people can understand their genetic risks at no-cost." "The driving force behind this collaborative event is the shared missions of all our organizations, across the country, to advance progress in cardiovascular research, education, prevention and treatment," says Jayson Morgan, MD, FACC, Director Cardiovascular Services at Renown. "We will be joined by colleagues from Johns Hopkins, Cedars-Sinai, Scripps, University of New Mexico Health Sciences, University of Utah, Medical College of Wisconsin, the Metabolic Institute of America and locally- with experts from Renown's Institute for Heart & Vascular Health/UNR Med, St. Mary's and Barton Health - to discuss contemporary trends in providing excellent cardiovascular care and prevention." New research will be presented each day, including: “Vaping and Electronic Cigarettes – The Hidden Epidemic: What the Clinician Needs to Know” Michael J. Blaha, MD, MPH, FACC, Professor of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Director of Clinical Research, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD “Optimizing Glycemic Control in the Inpatient Setting” Kendall M. Rogers, MD, CPE, FACP, SFHM, Professor, Department of Internal Medicine, University of New Mexico School of Medicine, Chief, Division of Hospital Medicine, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM “Perioperative Medicine Update”                                                                                                                                                                                             Barbara A. Slawski, MD, MS, SFHM Professor of Medicine & Orthopaedic Surgery, Chief, Section of Hospital Medicine, Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI “Understanding hATTR Amyloidosis: Clinical Presentation and Treatment Landscape” Jignesh K. Patel, MD, PhD, FACC, FRCP, FAST, FAHA, Clinical Professor of Medicine, Medical Director, Heart Transplant Program, Director, Cardiac Amyloid Program, Director, Heart Transplant Research, Cedars-Sinai Medical Center, Los Angeles, CA “Coronary Artery Calcium in 2021: Guideline-Endorsed and Ready for Prime Time” “The Evolving Landscape of Obesity Management – A 2021 Update” Ken Fujioka, MD, Director of the Center for Weight Management, Director of the Nutrition and Metabolic Research Center, Scripps Clinic, Department of Diabetes and Endocrine, San Diego, CA “The Evolving Landscape of Obesity Management – A 2021 Update” Ken Fujioka, MD, Director of the Center for Weight Management, Director of the Nutrition and Metabolic Research Center, Scripps Clinic, Department of Diabetes and Endocrine, San Diego, CA “Management of Atrial Fibrillation: Where We Are; Where We Are Headed” Matthew A. Cain, MD, Electrophysiologist, Renown Institute for Heart & Vascular Health, Renown Medical Group, Reno, NV "The Story of a Murmur” Abhilash Akinapelli, MD, Cardiac Valve & TAVR Program Director, Renown Institute for Heart & Vascular Health, Renown Medical Group, Reno, NV "Update on the Cardiovascular Effects of COVID-19” Siddharth Singh, MD, Assistant Director, Echo Fellowship Training Program, Smidt Heart Institute, Cedars-Sinai, Los Angeles, CA “Antibiotic Stewardship: How to Improve Our Prescribing for Now and Later”                                                                                                                            Valerie M. Vaughn, MD, MSc, FACP, FHM, Assistant Professor, Instructional Track Director of Hospital Medicine Research, Division of General Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT "Emerging Trends in the Clinical Management of VTE”                                                                                                                                                                Victor F. Tapson, MD, FCCP, FRCP, Director, Clinical Research for the Women’s Guild Lung Institute, Director, Venous Thromboembolism & Pulmonary Vascular Disease Research Program, Associate Director, Pulmonary and Critical Care Division, Cedars-Sinai Medical Center, Los Angeles, CA “Contemporary Approach to the Management of Diabetes as a Cardiovascular Disease”                                                                                               Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, Medical Director & Principal Investigator, Metabolic Institute of America, Tarzana, CA The Arthur J Lurie, MD Memorial Dinner and Keynote Presentation, sponsored by the charitable Renown Foundation and the Lurie Family, is an evening ceremony to honor and memorialize the devotion and innovation of the lake Dr. Arthur J. Lurie, who personified humanitarian, medical and community service. Dr. Lurie devoted modernized heart surgery and was steadfast in his commitment to introduce new and groundbreaking techniques cardiovascular techniques to Nevada. He promoted and inspired life-changing research and advancements in heart surgery, as well as cancer research, until his passing in 1996. Medical professionals are invited to attend the 31st Annual Trends in Cardiovascular Medicine conference will take place at the Resort at Squaw Creek in Olympic Valley, CA from Friday, Nov. 5 through Sunday, Nov. 7, 2021. Those interested in registering or learning more may visit www.renown.org/trends. The clinical team at Renown Institute for Heart and Vascular Health is the recipient of a number of national awards for outstanding clinical care and service, including: In U.S. News and World Report Best Hospital rankings for 2021, Renown Regional Medical Center - #1 in the State of Nevada for 2021. No other hospital in Nevada earned recognition from U.S. News. Renown Regional Medical Center is High Performing, its highest rating possible, for Heart Failure and Chronic Obstructive Pulmonary Disease. Awarded by the American College of Surgeons for the Renown Regional earned America's 100 Best Hospitals for Critical Care Award (2021) for Superior clinical outcomes in treating pulmonary embolism, respiratory system failure, sepsis, and diabetic emergencies. Regional also earned the Pulmonary Care Excellence Award™ (2021), for superior outcomes. Designated Level II Trauma Center. For the 30th year, Renown Regional Medical Center is northern Nevada's only designated level II trauma center. Renown Regional awarded The Get with the Guidelines - Heart Failure Gold Plus Quality Achievement award for continually ensuring heart failure patients receive the most appropriate treatment according to nationally recognized, research-based guidelines, as well as AHA's mission: Lifeline Gold Receiving honor for the treatment of patients who suffer severe heart attacks. American College of Cardiology's NCDR Chest Pain-MI Registry Platinum Performance Achievement Award. Renown Regional Medical Center is one of only 225 hospitals nationwide to receive the honor. The award recognizes Renown's success in implementing a higher standard of care for heart attack patients and signifies that Renown has reached an aggressive goal of treating these patients to standard levels of care as outlined by the American College of Cardiology/American Heart Association clinical guidelines and recommendations.  To make an appointment with a provider at Renown's Institute for Heart and Vascular Health, request that your primary care provider make a referral. For more information on Renown's Institute for Heart and Vascular Health, visit renown.org/Health-Services/Heart-Care.     About Renown Health Renown Health is a locally governed, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. In U.S. News and World Report Best Hospital rankings, Renown Regional Medical Center was listed #1 in the State of Nevada. Renown has a long tradition and commitment to improve the care and the health of our community. For more information, visit renown.org.

Read More About Leading Experts Convene in Tahoe to Focus on Scientific Advancements and the Prevention of Cardiovascular Disease, the #1 Cause of Death Globally